凝血酶激活的纤溶抑制物检测临床应用进展

doi:10.3969/j.issn.1673-8640.2024.10.016

摘要/Abstract

摘要：

凝血酶激活的纤溶抑制物（TAFI）是一种主要由肝脏合成分泌的，具有血浆羧肽酶样活性的单链糖蛋白，在血浆中以酶原的形式存在。传统的TAFI检测方法为酶联免疫吸附试验（ELISA）、酶学测定和功能学检测。近年来，免疫比浊法和同位素稀释质谱法等新的检测方法被开发并普及，推动了TAFI在深静脉血栓、心脑血管疾病、出血性疾病和炎症性疾病中的临床应用。文章对TAFI的生理功能进行介绍，并总结TAFI检测技术及其检测原理，梳理TAFI的临床应用价值，旨在更深入地了解TAFI，为血栓性疾病的防治提供参考。

关键词: 凝血酶激活的纤溶抑制物, 检测, 临床应用, 实验诊断

Abstract:

Thrombin-activatable fibrinolysis inhibitor（TAFI）is a single chain glycoprotein with plasma carboxypeptidase-like activity，which is synthesized and secreted mainly by the liver，and it exists in plasma in the form of zymogen. The traditional methods of TAFI deterimination include enzyme-linked immunosorbent assay（ELISA），enzymatic assay and functional assay. In the recent years，new determination methods，such as immunoturbidimetry and isotope dilution mass spectrometry，have been developed and popularized，promoting the clinical application of TAFI in deep vein thrombosis，cardiovascular and cerebrovascular diseases，hemorrhagic diseases and inflammatory diseases. This review introduces the physiological function of TAFI，summarizes the determination technologies and determination principles of TAFI，and it reviews the clinical application value of TAFI，aiming to understand the role of TAFI for thrombotic diseases and provide a reference for prevention and treatment.

Key words: Thrombin-activatable fibrinolysis inhibitor, Determination, Clinical application, Experimental diagnosis

中图分类号:

R446.11

崔巍琦, 欧心旸, 赵春贺, 夏薇, 曲林琳. 凝血酶激活的纤溶抑制物检测临床应用进展[J]. 检验医学, 2024, 39(10): 1021-1026.

CUI Weiqi, OU Xinyang, ZHAO Chunhe, XIA Wei, QU Linlin. Progress of thrombin-activatable fibrinolysis inhibitor determination in clinical application[J]. Laboratory Medicine, 2024, 39(10): 1021-1026.

图/表 1

参考文献 50

[1]	《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36):2861-2888.
[2]	杨萍, 王颖. 凝血酶激活的纤溶抑制物与血栓性疾病[J]. 血栓与止血学, 2006, 12(5):231-233.
[3]	HENDRIKS D, SCHARPÉ S, VAN SANDE M, et al. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N[J]. J Clin Chem Clin Biochem, 1989, 27(5):277-285.
[4]	CÔTÉ H C, STEVENS W K, BAJZAR L, et al. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin(R155A,R271A,and R284A)[J]. J Biol Chem, 1994, 269(15):11374-11380.
[5]	SILLEN M, DECLERCK P J. Thrombin activatable fibrinolysis inhibitor(TAFI):an updated narrative review[J]. Int J Mol Sci, 2021, 22(7):3670.
[6]	LOGHMANI H, CONWAY E M. Exploring traditional and nontraditional roles for thrombomodulin[J]. Blood, 2018, 132(2):148-158. DOI PMID
[7]	CHRISTENSEN U. C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen[J]. FEBS Lett, 1985, 182(1):43-46. PMID
[8]	FLEURY V, ANGLÉS-CANO E. Characterization of the binding of plasminogen to fibrin surfaces:the role of carboxy-terminal lysines[J]. Biochemistry, 1991, 30(30):7630-7638.
[9]	PECHLIVANI N, KEARNEY K J, AJJAN R A. Fibrinogen and antifibrinolytic proteins:interactions and future therapeutics[J]. Int J Mol Sci, 2021, 22(22):12537.
[10]	HEYLEN E, WILLEMSE J, HENDRIKS D. An update on the role of carboxypeptidase U(TAFIa)in fibrinolysis[J]. Front Biosci(Landmark Ed), 2011, 16(7):2427-2450.
[11]	BAJZAR L, NESHEIM M E, TRACY P B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent[J]. Blood, 1996, 88(6):2093-2100. PMID
[12]	GUO X, MORIOKA A, KANEKO Y, et al. Arginine carboxypeptidase(CPR)in human plasma determined with sandwich ELISA[J]. Microbiol Immunol, 1999, 43(7):691-698.
[13]	GUIMARÃES A H, BERTINA R M, RIJKEN D C. A new functional assay of thrombin activatable fibrinolysis inhibitor[J]. J Thromb Haemost, 2005, 3(6):1284-1292. PMID
[14]	VAN TILBURG N H, ROSENDAAL F R, BERTINA R M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis[J]. Blood, 2000, 95(9):2855-2859. PMID
[15]	WILLEMSE J L, HENDRIKS D F. Measurement of procarboxypeptidase U(TAFI)in human plasma:a laboratory challenge[J]. Clin Chem, 2006, 52(1):30-36.
[16]	LEEBEEK F W, GOOR M P, GUIMARAES A H, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke[J]. J Thromb Haemost, 2005, 3(10):2211-2218. DOI PMID
[17]	DAI H, SHI J, HE Q, et al. Dose-response relationship between thrombin-activatable fibrinolysis inhibitor(TAFI)and stroke:a Chinese case-control study[J]. Med Sci Monit, 2017, 23:4376-4381.
[18]	WHEELER J X, THELWELL C, RIGSBY P, et al. Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry[J]. Anal Biochem, 2022, 638:114413.
[19]	YILDIZ A, KATAR D, et al.SOYDA A Ö, Association of thrombin-activatable fibrinolysis inhibitor with acute pulmonary embolism[J]. Hamostaseologie, 2022, 42(3):180-184.
[20]	HARBSMEIER A N, ALTINTAS I, IVERSEN K, et al. Biomarkers and the post-thrombotic syndrome:a systematic review of biomarkers associated with the occurrence of the post-thrombotic syndrome after lower extremity deep venous thrombosis[J]. Phlebology, 2023, 38(9):577-598.
[21]	MA J, CUI L, HUO W, et al. Correlation between deep venous thrombosis and inflammation in patients after implantation of permanent pacemaker[J]. Iran J Public Health, 2020, 49(1):30-36. PMID
[22]	倪萍, 张斯蒙, 田沛茹, 等. 凝血酶激活的纤溶抑制剂水平与冠心病关系的Meta分析[J]. 中国循证心血管医学杂志, 2019, 11(2):155-159.
[23]	赵梦男. 血清凝血酶激活的纤溶抑制物水平与冠心病关系的病例对照研究[D]. 沈阳: 中国医科大学, 2021.
[24]	ZHAO M, ZHAO D, LI Y, et al. A case-control study of the dose-response relationship between thrombin activatable fibrinolysis inhibitor and acute myocardial infarction[J]. Front Cardiovasc Med, 2022, 9:823381.
[25]	MERTENS J C, LEENAERTS D, BROUNS R, et al. Procarboxypeptidase U(proCPU,TAFI,proCPB2)in cerebrospinal fluid during ischemic stroke is associated with stroke progression,outcome and blood-brain barrier dysfunction[J]. J Thromb Haemost, 2018, 16(2):342-348.
[26]	MERTENS J C, BOISSEAU W, LEENAERTS D, et al. Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke[J]. J Thromb Haemost, 2020, 18(12):3325-3335.
[27]	倪萍. 血清凝血酶激活的纤溶抑制物水平与老年人原发性高血压关系的病例对照研究[D]. 沈阳: 中国医科大学, 2019.
[28]	陈红. 血浆TAFI和血清Hcy、FIB、D-D联合检测对急性脑出血患者术后再出血的诊断价值分析[J]. 中外医疗, 2021, 40(19):9-12.
[29]	WYSEURE T, YANG T, ZHOU J Y, et al. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding[J]. JCI Insight, 2019, 4(19):e128379.
[30]	WYSEURE T, COOKE E J, DECLERCK P J, et al. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding[J]. Blood, 2018, 132(15):1593-1603. DOI PMID
[31]	LEUNG L L, MYLES T, NISHIMURA T, et al. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B(or TAFI)[J]. Mol Immunol, 2008, 45(16):4080-4083.
[32]	RADOVANOVIĆ-DINIĆ B, TEŠIĆ-RAJKOVIĆ S, IGNJATOVIC A, et al. Thrombin activatable fibrinolysis inhibitor as an indicator of the severity of acute pancreatitis[J]. Turk J Gastroenterol, 2018, 29(4):488-493.
[33]	YÜZBAŞIOĞLU B, USTAOĞLU M, YÜZBAŞIOĞLU Ş, et al. Levels of TAFI,TFPI and ADAMTS-13 in inflammatory bowel disease[J]. Turk J Gastroenterol, 2019, 30(12):1025-1029.
[34]	YOSHIDA K, TAKABAYASHI T, IMOTO Y, et al. Increased thrombin-activatable fibrinolysis inhibitor in response to sublingual immunotherapy for allergic rhinitis[J]. Laryngoscope, 2021, 131(11):2413-2420.
[35]	IMOTO Y, KATO A, TAKABAYASHI T, et al. Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2019, 144(6):1566-1574. DOI PMID
[36]	VOLLRATH J T, MARZI I, HERMINGHAUS A, et al. Post-traumatic sepsis is associated with increased C5a and decreased TAFI levels[J]. J Clin Med, 2020, 9(4):1230.
[37]	HORI Y, GABAZZA E C, YANO Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients[J]. J Clin Endocrinol Metab, 2002, 87(2):660-665.
[38]	刘丹, 倪铭晞, 佟鑫垚, 等. 2型糖尿病肾病患者外周血IL-4、INF-γ及TAFI表达及其与肾小球滤过功能的相关性[J]. 川北医学院学报, 2023, 38(4):510-513.
[39]	熊超, 曾灵芝, 廖立潇. TAFI在乳腺癌患者中的水平变化及临床意义[J]. 江西医药, 2017, 52(7):620-622.
[40]	谢英华, 杨秋继, 马骏峰, 等. 脑肿瘤患者围手术期纤溶的变化及分析[J]. 血栓与止血学, 2019, 25(5):721-724.
[41]	张钧. 胃癌患者血浆TAFI及TAT的变化及其临床意义[J]. 实用癌症杂志, 2016, 31(3):390-392.
[42]	徐莹, 薛国辉, 华琳. 系统性红斑狼疮患者中TAFI、PAI-1及t-PA水平变化及其与疾病活动度的关系[J]. 医学信息, 2020, 33(20):54-56.
[43]	GROSSO G, VIKERFORS A, WOODHAMS B, et al. Thrombin activatable fibrinolysis inhibitor(TAFI)-a possible link between coagulation and complement activation in the antiphospholipid syndrome(APS)[J]. Thromb Res, 2017, 158:168-173.
[44]	FUJIWARA A, TAGUCHI O, TAKAGI T, et al. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma[J]. Lung, 2012, 190(2):189-198. DOI PMID
[45]	吕治安, 王娟妮, 杨艳艳. TIMP-2、TAFI与CyPA水平联合检测用于肾衰竭疾病相关进程的临床价值分析[J]. 中国中西医结合肾病杂志, 2022, 23(1):30-32.
[46]	戴海英, 薛晓婕, 汪宏良. 血浆凝血酶激活的纤溶抑制物与肾病综合征的关系研究[J]. 国际检验医学杂志, 2018, 39(14):1725-1729.
[47]	WILLEMSE J L, HEYLEN E, NESHEIM M E, et al. Carboxypeptidase U(TAFIa):a new drug target for fibrinolytic therapy?[J]. J Thromb Haemost, 2009, 7(12):1962-1971.
[48]	BUNNAGE M E, BLAGG J, STEELE J, et al. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis[J]. J Med Chem, 2007, 50(24):6095-6103.
[49]	VAN MOORSEL M V A, POOLEN G C, KOEKMAN C A, et al. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow[J]. J Thromb Haemost, 2022, 20(5):1213-1222. DOI PMID
[50]	张勤, 姚瀚鑫, 刘玲玲, 等. 长春地区血浆凝血酶激活纤溶抑制物参考区间的建立[J]. 中国实验诊断学, 2022, 26(9):1353-1355.